Coherus Biosciences | CHRS - Ebit

Stock Price
1.61
Daily Change
-0.40 -19.90%
Monthly
0.63%
Yearly
36.44%
Q1 Forecast
2.39

Coherus Biosciences reported $-45.43M in EBIT for its fiscal quarter ending in March of 2025.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Akebia Therapeutics USD 13.51M 27.82M Mar/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -1.7M 8.47M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Coherus Biosciences USD -45.43M 3.19M Mar/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Fujifilm JPY 89.96B 6.77B Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Merck USD 6.24B 1.32B Dec/2025
Myriad Genetics USD -5.5M 11.1M Mar/2025
Pacira USD 13.15M 2.92M Sep/2025
Perrigo USD 93.4M 37.8M Sep/2025
Pfizer USD 4.65B 71M Dec/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Teva Pharmaceutical Industries USD 577M 491M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xencor USD -47.52M 24.69M Sep/2025
Zoetis USD 835M 140M Dec/2025